IRIS
MAZZASCHI, GIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.392
NA - Nord America 1.377
AS - Asia 538
AF - Africa 27
OC - Oceania 4
SA - Sud America 2
Totale 3.340
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.371
IT - Italia 500
IE - Irlanda 323
CN - Cina 276
SE - Svezia 266
SG - Singapore 187
DE - Germania 71
AT - Austria 53
IN - India 39
FI - Finlandia 37
FR - Francia 35
CI - Costa d'Avorio 26
CZ - Repubblica Ceca 25
BE - Belgio 21
GB - Regno Unito 19
TR - Turchia 16
RU - Federazione Russa 11
UA - Ucraina 8
NL - Olanda 7
CA - Canada 6
HK - Hong Kong 5
LU - Lussemburgo 5
AU - Australia 4
IR - Iran 4
KR - Corea 4
BG - Bulgaria 2
BR - Brasile 2
ID - Indonesia 2
IL - Israele 2
MD - Moldavia 2
CH - Svizzera 1
ES - Italia 1
JP - Giappone 1
LT - Lituania 1
MK - Macedonia 1
MT - Malta 1
PH - Filippine 1
PL - Polonia 1
RS - Serbia 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 3.340
Salva come PNG Salva come JPEG
Città #
Dublin 320
Chandler 306
Boardman 132
Ashburn 131
Singapore 128
Parma 126
Ann Arbor 123
Shanghai 93
New York 56
Vienna 53
Beijing 50
Bologna 50
Bremen 41
Princeton 37
Dearborn 31
Helsinki 27
Abidjan 26
Milan 24
Nanjing 24
West Jordan 22
Brussels 19
Verona 18
Rome 17
Des Moines 16
Brno 15
Rio Saliceto 15
Chicago 14
Los Angeles 14
Wilmington 14
Santa Clara 13
Fremont 11
Pune 11
Dallas 10
Jinan 10
Torrile 10
Izmir 9
Trento 9
Ardea 8
Falls Church 8
Guangzhou 8
Reggio Emilia 8
San Mateo 8
Hangzhou 7
Hefei 7
Nanchang 7
Boston 6
Houston 6
Kocaeli 6
London 6
Modena 6
Olomouc 6
Amsterdam 5
Bolzano 5
Hebei 5
Jiaxing 5
Kunming 5
Norwalk 5
Redwood City 5
Seattle 5
Verdellino 5
Zhengzhou 5
Assago 4
Busto Arsizio 4
Chiari 4
Florence 4
Frankfurt am Main 4
Grafing 4
Kochi 4
Kolkata 4
Montreal 4
Naples 4
Trieste 4
Wayne 4
Woodbridge 4
Atlanta 3
Brescia 3
Changsha 3
Collecchio 3
Genova 3
Kyiv 3
Lanzhou 3
Lonato 3
Melbourne 3
Munich 3
San Giuliano Milanese 3
Scandiano 3
Shenyang 3
Tianjin 3
Washington 3
Alcamo 2
Bagnolo in Piano 2
Bali 2
Bhubaneswar 2
Brooklyn 2
Cambridge 2
Central 2
Cernusco sul Naviglio 2
Cerreto Guidi 2
Chisinau 2
Daejeon 2
Totale 2.291
Salva come PNG Salva come JPEG
Nome #
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 115
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients 115
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 113
Imatinib mesylate-induced cardiomyopathy involves resident cardiac progenitors 96
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 91
Low PD-1 expression in Cytotoxic CD8+ Tumor infiltrating Lymphocytes Confers an Immune Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value 87
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 84
INTEGRATION OF TISSUE PD-1/PD-L1 IMMUNE CHECKPOINT WITH COMPUTED TOMOGRAPHY (CT) BASED TEXTURE ANALYSIS EXHIBITS HIGH PROGNOSTIC IMPACE ON SURGICALLY RESECTED NON SMALL CELL LUNG CANCER (NSCLC) 84
Blood and lymphatic vessels contribute to the impact of the immune microenvironment on clinical outcome in non-small-cell lung cancer 78
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 74
Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis 74
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 73
Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC 73
SURGICAL SAMPLING IS AN EMERGING ISSUE IN THE ASSESSMENT OF THE IMMUNE CONTEXTURE IN NON SMALL CELL LUNG CANCER (NSCLC) 71
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 70
Favorable clinical outcome and response to immunotherapy share a common PD-L1/PD-1 based NSCLC immune contexture 69
Spatial architecture of tumour-infiltrating lymphocytes as a prognostic parameter in resected non-small-cell lung cancer 65
BLOOD AND LYMPHATIC VESSELS CONSTITUTE AN ESSENTIAL COMPONENT OF THE IMMUNE MICROENVIRONMENT AND ITS IMPACT ON NON SMALL CELL LUNG CANCER (NSCLC) CLINICAL OUTCOME 64
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 64
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 64
Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer 64
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 63
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 63
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 61
IMPACT OF THE TISSUE DISTRIBUTION OF SUBPOPULATIONS OF TILS AND PD-L1 EXPRESSION ON THE CLINICAL OUTCOME OF NSCLC 60
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 59
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 56
Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma 54
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 51
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 49
THE ROLE OF BLOOD CHOLESTEROL QUALITY IN PATIENTS WITH ADVANCED CANCER RECEIVING IMMUNE CHECKPOINT INHIBITORS 45
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 45
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 45
Dynamic evaluation of circulating mirna profile in egfr‐ mutated nsclc patients treated with egfr‐tkis 44
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology 42
Differentially regulated high-throughput CT imaging features correlate to distinct tumor immune contextures portraying a radiomic signature with prognostic impact on surgically resected NSCLC 42
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study 41
The role of c-met as a biomarker and player in innate and acquired resistance in non-small-cell lung cancer: Two new mutations warrant further studies 38
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 37
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status 37
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 36
Cytoreductive nephrectomy in the era of targeted- And immuno- therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature 36
91 Circulating lipid profile as a prognostic factor in patients with advanced solid tumors treated with immune checkpoint inhibitors 34
227P Sexual dimorphism in immune profile of early and advanced NSCLC 34
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 34
The radiological appearances of lung cancer treated with immunotherapy: a review 33
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis 33
Integration of tissue and circulating parameters identifies a favorable immune profile in NSCLC patients treated with nivolumab 28
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 25
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score 25
Evaluation of PBRM1, PD-L1, CD31, and CD4/CD8 ratio as a predictive signature of response to VEGFR-TKI–based therapy in patients with metastatic renal cell carcinoma (mRCC) with IMDC intermediate prognosis: Results from the APAChE-I Study 25
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 25
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer 24
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review 23
Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study 22
Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario 21
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 21
What Is the Real Impact of Concomitant Antibiotics or Proton Pump Inhibitors on Efficacy of Atezolizumab-Based Regimens in Patients With NSCLC? 20
Drug-drug interactions (DDIs) in elderly patients with metastatic renal cell carcinoma (mRCC) treated with cabozantinib within the multicenter prospective trial ZEBRA/Meet-URO 9 20
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 20
Deciphering the different patterns of acquired resistance in immunotherapy treated NSCLC patients through an integrated clinical and blood immuneinflammatory profiling 18
Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictors 17
Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma 17
Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer 17
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 16
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors 14
Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences 14
Divergent PD-1 expression in tissue and circulating CD8 lymphocytes defines an immune profile predictive of the response to nivolumab in advanced NSCLC 14
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 14
Exploring genetic and immune underpinnings of the sexual dimorphism in tumor response to immune checkpoints inhibitors: A narrative review 13
Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non–Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors 12
9P Identification of a μCT-based radiomic signature of CD8+ tumour infiltrating lymphocytes in an orthotopic murine model 12
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC 11
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients 11
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations 11
Advanced CT imaging features reflect distinct tissue immune profiles and exhibit high prognostic impact on NSCLC 10
Identification of a radio-immune signature with high prognostic value in surgically resected NSCLC 9
Immune checkpoint inhibitors in hepatocellular cancer patient with congenital haemophilia A 9
5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC 9
Burnout and Oncology: an irreparable paradigm or a manageable condition? Prevention strategies to reduce Burnout in Oncology Health Care Professionals 8
Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC 8
Abscopal effect as part of treatment of oligometastatic head and neck cancer: A case report 8
Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy 7
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 7
Evaluation of PBRM1, PD-L1, CD31 and CD4/CD8 ratio as predictive biomarkers of response to VEGFR-TKI-based therapy in metastatic renal cell carcinoma (mRCC) patients with IMDC intermediate prognosis: Results from the APAChE-I study 6
Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups 6
The distinct prognostic impact of circulating lipid profile according to neutrophil to lymphocyte ratio in patients with advanced solid tumors treated with immune check point inhibitors. 5
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC 5
1599P Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: A retrospective single-center observational study 5
A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study 5
Totale 3.477
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.174
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.174
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020174 0 0 1 11 15 33 19 15 10 53 10 7
2020/2021246 10 11 10 23 33 33 16 18 23 16 35 18
2021/2022265 13 13 15 19 5 12 57 10 6 10 21 84
2022/20231.292 116 126 71 109 143 141 38 73 388 7 56 24
2023/2024872 32 60 28 36 110 157 97 35 62 80 49 126
2024/2025432 92 176 164 0 0 0 0 0 0 0 0 0
Totale 3.477